PHATHOM PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $12.44 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.44, a 44.26% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $9.76, a 3.08% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $10.07, a 70.95% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $34.66.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $7.17, a 45.48% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $13.15, a 63.43% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $35.96, a 22.65% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $29.32, a 9.11% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.44 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | $5.44 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $7.17 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $7.41 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $7.35 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $9.76 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $13.15 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $13.72 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $12.96 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $10.07 10-Q/A · filed 2024-06-14 | |||
| 2023-12-31 | $35.96 10-K/A · filed 2024-06-14 | |||
| 2023-09-30 | $36.53 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $34.28 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $34.66 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $29.32 10-K/A · filed 2024-06-14 | |||
| 2021-12-31 | $32.26 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $34.07 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $33.88 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |